Veloxis Pharmaceuticals Announces NDA Submission for EnvarsusA in Kidney Transplant Recipients

The submission is based on the entire data set from the company's clinical development program that comprised 25 studies and enrolled over 1000 patients, including two pivotal clinical trials, studies 3001 and 3002.

http://www.sys-con.com/node/2910466